Chemgenex Pharmaceuticals Overview
- Year Founded
-
1958
- Status
-
Acquired/Merged
- Employees
-
19
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$227M
Chemgenex Pharmaceuticals General Information
Description
Developer of therapeutics in the areas of oncology, diabetes, obesity and depression. The company develops small molecules with new mechanisms of action to treat malignancies with significant unmet medical needs.
Contact Information
Corporate Office
- Level 4 199 Moorabool St
- P.O. Boc 1069
- Geelong, Victoria 3220
- Australia
Corporate Office
- Level 4 199 Moorabool St
- P.O. Boc 1069
- Geelong, Victoria 3220
- Australia
Chemgenex Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Merger/Acquisition | 29-Mar-2011 | $227M | Completed | Generating Revenue | ||
| 7. PIPE | 22-Oct-2010 | Completed | Generating Revenue | |||
| 6. PIPE | 01-Apr-2009 | Completed | Generating Revenue | |||
| 5. PIPE | 18-Sep-2008 | Completed | Generating Revenue | |||
| 4. PIPE | 15-Apr-2007 | Completed | Generating Revenue | |||
| 3. PIPE | 01-May-2006 | Completed | Generating Revenue | |||
| 2. PIPE | 01-Jan-2005 | $6.29M | $10.7M | Completed | Generating Revenue | |
| 1. PIPE | 14-Jul-2004 | $4.38M | $4.38M | Completed | Generating Revenue |
Chemgenex Pharmaceuticals Patents
Chemgenex Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2005095610-A1 | Nucleic acid expressed in the hypothalamus or muscle tissue and uses thereof in diagnoses | Inactive | 31-Mar-2004 | ||
| WO-2005090378-A1 | Ligands of the molecule fit (agt-121) and their pharmaceutical use | Inactive | 16-Mar-2004 | ||
| WO-2005074923-A1 | Methods and compositions | Inactive | 03-Feb-2004 | ||
| WO-2005026358-A1 | Polymorphisms in selenoprotein s | Inactive | 18-Sep-2003 | ||
| WO-2005026358-A9 | Polymorphisms in selenoprotein s | Inactive | 18-Sep-2003 | C07K14/47 |
Chemgenex Pharmaceuticals Signals
Chemgenex Pharmaceuticals Former Investors (5)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Allan Gray Australia | Mutual Fund | Minority | ||
| Alta Partners | Venture Capital | Minority | ||
| GBS Venture Partners | Venture Capital | Minority | ||
| Merck Sante | Corporation | Minority | ||
| QIC | Sovereign Wealth Fund | Minority |
Chemgenex Pharmaceuticals Acquisitions (1)
Chemgenex Pharmaceuticals’s most recent deal was a Merger/Acquisition with ChemGenex Therapeutics for . The deal was made on 21-Jun-2004.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| ChemGenex Therapeutics | 21-Jun-2004 | Merger/Acquisition | Drug Discovery |
Chemgenex Pharmaceuticals FAQs
-
When was Chemgenex Pharmaceuticals founded?
Chemgenex Pharmaceuticals was founded in 1958.
-
Where is Chemgenex Pharmaceuticals headquartered?
Chemgenex Pharmaceuticals is headquartered in Geelong, Australia.
-
What is the size of Chemgenex Pharmaceuticals?
Chemgenex Pharmaceuticals has 19 total employees.
-
What industry is Chemgenex Pharmaceuticals in?
Chemgenex Pharmaceuticals’s primary industry is Biotechnology.
-
Is Chemgenex Pharmaceuticals a private or public company?
Chemgenex Pharmaceuticals is a Private company.
-
What is the current valuation of Chemgenex Pharmaceuticals?
The current valuation of Chemgenex Pharmaceuticals is .
-
What is Chemgenex Pharmaceuticals’s current revenue?
The current revenue for Chemgenex Pharmaceuticals is .
-
How much funding has Chemgenex Pharmaceuticals raised over time?
Chemgenex Pharmaceuticals has raised $71M.
-
Who are Chemgenex Pharmaceuticals’s investors?
Allan Gray Australia, Alta Partners, GBS Venture Partners, Merck Sante, and QIC have invested in Chemgenex Pharmaceuticals.
-
When was Chemgenex Pharmaceuticals acquired?
Chemgenex Pharmaceuticals was acquired on 29-Mar-2011.
-
Who acquired Chemgenex Pharmaceuticals?
Chemgenex Pharmaceuticals was acquired by Cephalon.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process